FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2145480852> ?p ?o ?g. }

• W2145480852 endingPage "e139" @default.
• W2145480852 startingPage "e132" @default.
• W2145480852 abstract "Rituximab is being increasingly used in children with idiopathic nephrotic syndrome resistant to standard treatments. In spite of good initial response, rituximab responders always remain prone to further relapse, necessitating either repeat course of rituximab or addition of another steroid-sparing immunosuppressant.A retrospective analysis of baseline clinico-pathologic presentation and treatment outcome (complete remission, partial remission, or no response) was performed among 24 children with refractory-idiopathic SRNS over a follow-up period of 24 months. Children received 2 to 4 rituximab infusions (375 mg/m(2) weekly) depending on circulating B-cell level. At 3-month follow-up, a second course of rituximab was administered (if >5 B cells/mm(3)) along with MMF (1200 mg/m(2) per day) maintenance therapy.Of 24 patients, 54% (13/24) and 46% (11/24) had minimal change disease and focal segmental glomerulosclerosis, respectively, on renal histopathology. After the first course of rituximab, 21% (5/24) of children achieved complete remission; however, most (4/5) of them relapsed again at a median interval of 53 (interquartile range 46-72) days. Depending on response to the first course of rituximab, MMF was started on 15 children at 3 months. After 6 months, 67% (10/15) of children on MMF achieved complete remission and 33% (5/15) remained at partial remission. At 24 months overall, 25% (6/24) and 42% (10/24) of children were in complete remission and partial remission, respectively; 33% (5/15) of children continued sustained complete remission after postrituximab-MMF maintenance therapy in comparison with no sustained complete remission with rituximab alone at 24 months (P < .001).MMF may be an effective and safe maintenance therapy to consider as an additive immunosuppressant after induction with rituximab in maintaining remission among children with refractory SRNS." @default.
• W2145480852 created "2016-06-24" @default.
• W2145480852 creator A5006636492 @default.
• W2145480852 creator A5024949529 @default.
• W2145480852 creator A5028148740 @default.
• W2145480852 date "2015-07-01" @default.
• W2145480852 modified "2023-09-30" @default.
• W2145480852 title "Mycophenolate Mofetil Following Rituximab in Children With Steroid-Resistant Nephrotic Syndrome" @default.
• W2145480852 cites W1977991117 @default.
• W2145480852 cites W1981507875 @default.
• W2145480852 cites W1983663249 @default.
• W2145480852 cites W1988812807 @default.
• W2145480852 cites W1989228601 @default.
• W2145480852 cites W1991118583 @default.
• W2145480852 cites W2003607385 @default.
• W2145480852 cites W2003950996 @default.
• W2145480852 cites W2006175193 @default.
• W2145480852 cites W2018799387 @default.
• W2145480852 cites W2038580813 @default.
• W2145480852 cites W2046672031 @default.
• W2145480852 cites W2054627468 @default.
• W2145480852 cites W2088812049 @default.
• W2145480852 cites W2090207809 @default.
• W2145480852 cites W2118072881 @default.
• W2145480852 cites W2122855609 @default.
• W2145480852 cites W2161254226 @default.
• W2145480852 cites W2167019152 @default.
• W2145480852 cites W2171767062 @default.
• W2145480852 cites W2316086035 @default.
• W2145480852 doi "https://doi.org/10.1542/peds.2015-0486" @default.
• W2145480852 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26101364" @default.
• W2145480852 hasPublicationYear "2015" @default.
• W2145480852 type Work @default.
• W2145480852 sameAs 2145480852 @default.
• W2145480852 citedByCount "42" @default.
• W2145480852 countsByYear W21454808522015 @default.
• W2145480852 countsByYear W21454808522016 @default.
• W2145480852 countsByYear W21454808522017 @default.
• W2145480852 countsByYear W21454808522018 @default.
• W2145480852 countsByYear W21454808522019 @default.
• W2145480852 countsByYear W21454808522020 @default.
• W2145480852 countsByYear W21454808522021 @default.
• W2145480852 countsByYear W21454808522022 @default.
• W2145480852 countsByYear W21454808522023 @default.
• W2145480852 crossrefType "journal-article" @default.
• W2145480852 hasAuthorship W2145480852A5006636492 @default.
• W2145480852 hasAuthorship W2145480852A5024949529 @default.
• W2145480852 hasAuthorship W2145480852A5028148740 @default.
• W2145480852 hasConcept C119060515 @default.
• W2145480852 hasConcept C121332964 @default.
• W2145480852 hasConcept C126322002 @default.
• W2145480852 hasConcept C141071460 @default.
• W2145480852 hasConcept C142424586 @default.
• W2145480852 hasConcept C187212893 @default.
• W2145480852 hasConcept C2776694085 @default.
• W2145480852 hasConcept C2777747828 @default.
• W2145480852 hasConcept C2778283404 @default.
• W2145480852 hasConcept C2778415529 @default.
• W2145480852 hasConcept C2778715236 @default.
• W2145480852 hasConcept C2778720950 @default.
• W2145480852 hasConcept C2778930706 @default.
• W2145480852 hasConcept C2779338263 @default.
• W2145480852 hasConcept C2780091579 @default.
• W2145480852 hasConcept C2780368995 @default.
• W2145480852 hasConcept C2780653079 @default.
• W2145480852 hasConcept C3018657049 @default.
• W2145480852 hasConcept C71924100 @default.
• W2145480852 hasConcept C87355193 @default.
• W2145480852 hasConcept C90924648 @default.
• W2145480852 hasConceptScore W2145480852C119060515 @default.
• W2145480852 hasConceptScore W2145480852C121332964 @default.
• W2145480852 hasConceptScore W2145480852C126322002 @default.
• W2145480852 hasConceptScore W2145480852C141071460 @default.
• W2145480852 hasConceptScore W2145480852C142424586 @default.
• W2145480852 hasConceptScore W2145480852C187212893 @default.
• W2145480852 hasConceptScore W2145480852C2776694085 @default.
• W2145480852 hasConceptScore W2145480852C2777747828 @default.
• W2145480852 hasConceptScore W2145480852C2778283404 @default.
• W2145480852 hasConceptScore W2145480852C2778415529 @default.
• W2145480852 hasConceptScore W2145480852C2778715236 @default.
• W2145480852 hasConceptScore W2145480852C2778720950 @default.
• W2145480852 hasConceptScore W2145480852C2778930706 @default.
• W2145480852 hasConceptScore W2145480852C2779338263 @default.
• W2145480852 hasConceptScore W2145480852C2780091579 @default.
• W2145480852 hasConceptScore W2145480852C2780368995 @default.
• W2145480852 hasConceptScore W2145480852C2780653079 @default.
• W2145480852 hasConceptScore W2145480852C3018657049 @default.
• W2145480852 hasConceptScore W2145480852C71924100 @default.
• W2145480852 hasConceptScore W2145480852C87355193 @default.
• W2145480852 hasConceptScore W2145480852C90924648 @default.
• W2145480852 hasIssue "1" @default.
• W2145480852 hasLocation W21454808521 @default.
• W2145480852 hasLocation W21454808522 @default.
• W2145480852 hasOpenAccess W2145480852 @default.
• W2145480852 hasPrimaryLocation W21454808521 @default.
• W2145480852 hasRelatedWork W1589180913 @default.
• W2145480852 hasRelatedWork W1765855 @default.
• W2145480852 hasRelatedWork W1979066197 @default.

• next